JP2015522522A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522522A5
JP2015522522A5 JP2015503431A JP2015503431A JP2015522522A5 JP 2015522522 A5 JP2015522522 A5 JP 2015522522A5 JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015522522 A5 JP2015522522 A5 JP 2015522522A5
Authority
JP
Japan
Prior art keywords
drug
prevent
relapse
nicotine
nicotine antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/033703 external-priority patent/WO2013148572A1/en
Publication of JP2015522522A publication Critical patent/JP2015522522A/ja
Publication of JP2015522522A5 publication Critical patent/JP2015522522A5/ja
Pending legal-status Critical Current

Links

JP2015503431A 2012-03-27 2013-03-25 刺激に誘発される薬物再発の阻止 Pending JP2015522522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615953P 2012-03-27 2012-03-27
US61/615,953 2012-03-27
PCT/US2013/033703 WO2013148572A1 (en) 2012-03-27 2013-03-25 Blocking of cue-induced drug reinstatement

Publications (2)

Publication Number Publication Date
JP2015522522A JP2015522522A (ja) 2015-08-06
JP2015522522A5 true JP2015522522A5 (https=) 2016-05-19

Family

ID=49261147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015503431A Pending JP2015522522A (ja) 2012-03-27 2013-03-25 刺激に誘発される薬物再発の阻止

Country Status (6)

Country Link
US (1) US20150051192A1 (https=)
EP (1) EP2830601A4 (https=)
JP (1) JP2015522522A (https=)
AU (1) AU2013239995A1 (https=)
CA (1) CA2908240A1 (https=)
WO (1) WO2013148572A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
EP2595632A1 (en) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US20150258110A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence using ibogaine
WO2015163844A1 (en) * 2014-04-21 2015-10-29 Demerx, Inc. N-substituted noribogaine prodrugs
CA3156514A1 (en) * 2019-10-01 2021-04-08 Mind Medicine, Inc. 18-MC FOR THE TREATMENT OF SUBSTANCE USE DISORDERS
WO2023278108A1 (en) * 2021-06-29 2023-01-05 Mind Medicine, Inc. 18-mc for treating obesity
WO2025117491A1 (en) * 2023-12-01 2025-06-05 Kuleon Llc Azepino analogs and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123220A0 (en) * 1995-08-08 1998-09-24 Albany Medical College Ibogamine congeners
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
EP1776121A2 (en) * 2004-08-13 2007-04-25 Omeros Corporation Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
CL2007002903A1 (es) * 2006-10-09 2008-04-18 Smithkline Beecham Corp Composicion que comprende a) al menos un antagonista del receptor nicotinico a3beta4; y b) al menos un metabolito de la nicotina; y uso para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco.
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
CN102348457A (zh) * 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US8785472B2 (en) * 2010-05-11 2014-07-22 National Cheng Kung University Use of dextromethorphan in treating addictive behavior or bipolar disorder

Similar Documents

Publication Publication Date Title
JP2015522522A5 (https=)
CY1123937T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
JP2016515522A5 (https=)
JP2015503422A5 (https=)
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
IL249837B (en) Inhaler for pulmonary delivery of active agents
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
JP2017514871A5 (https=)
MY179696A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HUE040609T2 (hu) GLP-1 vegyületek orális adagolása
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
SI3069720T1 (sl) Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
HK1231381A1 (zh) 癌症组合疗法
IL234701B (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
ZA201704026B (en) Oral octreotide administered in combination with other therapeutic agents
JP2015535291A5 (https=)
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
JP2014529579A5 (https=)